176 results
S-8
LSTA
Lisata Therapeutics Inc
17 Oct 22
Registration of securities for employees
4:02pm
attorneys’ fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation to the fullest extent permitted under … or investigation, provided that such person provides an undertaking required by the DGCL, to repay such advances if it is ultimately determined that such person
8-K/A
EX-99.1
LSTA
Lisata Therapeutics Inc
4 Oct 22
Other Events
4:42pm
, for failure to comply with the IRB's requirements, or may impose other conditions.
Companies generally divide the clinical investigation of a drug … of the change, it may require prior FDA approval before Cend can implement it. FDA regulations also require investigation and correction of any deviations
8-K
EX-10.2
nrnxr hy97h7l0tray
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
425
7jyewr54yezvcffsw4
15 Aug 22
Business combination disclosure
6:46am
424B3
klncuktt
29 Jul 22
Prospectus supplement
4:06pm
8-K
EX-2.1
qstvx3s2
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-2.3
dwgke3af67lm
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-2.2
n796yvg8ytpk5l7rtp2
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-10.2
8ewc je12pek
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-10.1
3ak1fn8coiq
4 Jun 21
Entry into a Material Definitive Agreement
4:44pm
8-K
EX-10.2
4zgzq89yszhn0h
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
8-K
EX-10.1
pcki2z46zqc 69q
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
424B3
o6hmtlk2 gt68bg35p
2 Sep 20
Prospectus supplement
4:03pm